Mesoionic xanthine analogues: antagonists of adenosine receptors. 1984

R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly

A variety of mesoionic xanthines including mesoionic thiazolo[3,2-alpha]pyrimidines, benzothiazolopyrimidines, and 1,3,4-thiadiazolo[3,2-alpha]pyrimidines were antagonists of A1-adenosine receptors (inhibition of binding of [3H]-cyclohexyladenosine) and A2-adenosine receptors (inhibition of 2-chloroadenosine-elicited accumulations of cyclic AMP) in brain tissue. Most of the compounds were less potent than theophylline and none were remarkably selective for A1- or A2-adenosine receptors. However, members of the thiadiazolopyrimidine class of mesoionics exhibited very low or no activity as antagonists of A2-adenosine receptors while exhibiting activity only 2-4-fold lower than that of theophylline at A1-adenosine receptors. Unlike the case for theophylline, the presence of a phenyl substituent in the five-membered ring did not enhance the potency of a mesoionic thiadiazolopyrimidine. The nature of the substituents on the mesoionic ring did not appear to have marked effects on potency unlike the marked effect of the nature of 1,3-substituents on activity of nonmesoionic xanthines. The benzothiazolo[3,2-alpha]pyrimidines were the most potent antagonists, being nearly as potent as theophylline at A1-adenosine receptors and somewhat more potent than theophylline at A2-adenosine receptors.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D011983 Receptors, Purinergic Cell surface proteins that bind PURINES with high affinity and trigger intracellular changes which influence the behavior of cells. The best characterized classes of purinergic receptors in mammals are the P1 receptors, which prefer ADENOSINE, and the P2 receptors, which prefer ATP or ADP. Methyladenine Receptors,Purine Receptors,Purinergic Receptor,Purinergic Receptors,Purinoceptors,Purine Receptor,Purinoceptor,Receptors, Methyladenine,Receptors, Purine,Receptor, Purine,Receptor, Purinergic
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
June 1981, Journal of medicinal chemistry,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
September 1985, Naunyn-Schmiedeberg's archives of pharmacology,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
June 1981, Journal of medicinal chemistry,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
February 1988, Biochemical pharmacology,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
August 2000, Bioorganic & medicinal chemistry,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
July 1982, European journal of pharmacology,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
November 2004, Chemistry & biodiversity,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
September 1998, Bioorganic & medicinal chemistry,
R A Glennon, and S M Tejani-Butt, and W Padgett, and J W Daly
March 1995, Journal of medicinal chemistry,
Copied contents to your clipboard!